GU Cancers Symposium 2014 - Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers to detect clinically significant disease: Results from the initial screening round of the IMPACT study - Session Highlights

SAN FRANCISCO, CA USA ( - Dr. Christos Mikropoulos reported on results from the initial screening round of the IMPACT study. IMPACT is an international consortium of 62 centers in 20 countries evaluating the use of targeted prostate cancer screening in men with BRCA1/2 mutations.

gucancerssympalt thumbIt is known that men with germline BRCA1/2 mutations have a higher risk of developing prostate cancer than non-carriers. 2 481 men (791 BRCA1 carriers, 531 BRCA1 controls; 731 BRCA2 carriers, 428 BRCA2 controls) of whom 199 (8%) presented with a PSA greater than 3ng/ml were enrolled into this study. One-hundred sixty-two prostate biopsies were performed and diagnosed 59 prostate cancers (18 BRCA1 carriers, ten BRCA1 controls; 24 BRCA2 carriers, seven BRCA2 controls). A significant difference in detecting intermediate- or high-risk disease was observed inBRCA2 carriers using a PSA threshold of 3.0 ng/ml, positive predictive value (PPV) of 48%, which is almost double that reported in population screening studies.

This early data support the use of targeted PSA screening, based on BRCA genotype (majority of BRCA1/2 mutation carriers), as these men are at higher risk of prostate cancer detection at the time of biopsy.

Highlights of a presentation by Christos Mikropoulos, MD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

The Institute of Cancer Research, London, England 

Written by Reza Mehrazin, MD, medical writer for

View Full 2014 GU Cancers Symposium Coverage